SecurityGNMX / Aevi Genomic Medicine, Inc. (58436Q203)
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Common Shares Outstanding59,337,265 shares (as of 2018-03-31)
Total Insiders14
Total Directors9
Total Officers4

Stock Insider Trading (from SEC Form 4)

Aevi Genomic Medicine, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

GNMX / Aevi Genomic Medicine, Inc. insiders include Piper Brian, Children's Hospital of Philadelphia Foundation, CLEMOW ALASTAIR J, BLECH ISAAC, Bayley Matthew D, and COLA MICHAEL F, Applebaum Scott, GANTZ WILBUR H, Duncan Barbara Gayle, BARER SOL J, BAUER EUGENE A, HARPER PHILIP R NEIL GARRY ARTHUR, GRANO JOSEPH J JR, .

Insider Roster

Insider Dir Off 10% Shares Owned
NEIL GARRY ARTHUR Chief Scientific Officer
X
Piper Brian CFO & Corporate Secretary
X
COLA MICHAEL F President and CEO, Director
X X
Bayley Matthew D Director
X
BAUER EUGENE A Director
X 165,715
CLEMOW ALASTAIR J Director
X 57,536
Duncan Barbara Gayle Director
X 59,524
GANTZ WILBUR H Director
X 71,073
GRANO JOSEPH J JR Director
X 113,847
BARER SOL J Director
X 1,547,732
Children's Hospital of Philadelphia Foundation 10% Owner
X 31,746,032
HARPER PHILIP R 10% Owner
X 5,179,819
BLECH ISAAC Director
X
Applebaum Scott Chief Legal Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2017-10-17 4 BARER SOL J P D 1.26 421,032 1,547,732 1,950,142
2017-10-17 4 GRANO JOSEPH J JR P D 1.26 -39,683 113,847 143,447
2017-10-17 4 NEIL GARRY ARTHUR P D 1.26 75,000 114,774 144,615
2017-10-17 4 GANTZ WILBUR H P D 1.26 39,683 71,073 89,552
2017-10-17 4 Duncan Barbara Gayle P D 1.26 59,524 59,524 75,000
2017-10-17 4 CLEMOW ALASTAIR J P D 1.26 19,841 57,536 72,495
2017-10-17 4 BAUER EUGENE A P D 1.26 19,841 165,715 208,801
2017-10-17 4 COLA MICHAEL F P D 1.26 119,047 218,483 275,289
2017-09-01 4 HARPER PHILIP R P D 1.2 83,775 5,179,819 6,215,783
2017-08-23 4 HARPER PHILIP R P D 1.2 5,700 5,096,044 6,115,253
2017-08-22 4 HARPER PHILIP R P D 1.2 4,661 5,090,344 6,108,413
2017-08-10 4 HARPER PHILIP R P D 1.19 20,470 5,085,683 6,051,963
2017-04-28 4 BARER SOL J P D 1.5667 100,000 1,126,700 1,765,201
2017-04-26 4 BARER SOL J P D 1.5434 100,000 1,026,700 1,584,609
2017-03-24 4 HARPER PHILIP R P D 1.6 53,826 5,065,213 8,104,341
2017-03-23 4 HARPER PHILIP R P D 1.6 4,705 5,011,387 8,018,219
2017-03-22 4 HARPER PHILIP R P D 1.79 1,000,000 5,006,682 8,961,961
2016-12-08 4 GRANO JOSEPH J JR P D 5.266 -3,000 74,164 390,548
2015-10-06 4 COLA MICHAEL F P D 6.50 38,460 99,436 646,334
2015-10-06 4 NEIL GARRY ARTHUR P D 6.50 15,384 39,774 258,531
2015-10-06 4 GRANO JOSEPH J JR By family foundation P I 6.50 15,384 71,164 462,566
2015-10-06 4 BARER SOL J By wife P I 6.50 153,846 926,700 6,023,550
2015-09-21 4 BLECH ISAAC By Trust S I 9.96 -94,825 1,802,003 17,947,950
2015-09-21 4 BLECH ISAAC By Trust X I 4.10 230,357 1,896,828
2015-03-20 4 BAUER EUGENE A S D 8.45 -50,000 145,874 1,232,635
2015-03-20 4 BARER SOL J P D 8.45 50,000 772,854 6,530,616
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
GNMX: Aevi Genomic Medicine Analysis and Research Report

2018-05-14 - Asif

Overview Aevi Genomic is a clinical stage biopharmaceutical company with an emphasis on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated novel therapies primarily for pediatric onset, life-altering diseases, including rare and orphan diseases. The company look to find treatments for genetically defined diseases for which there are limited therapeutic options currently available, with a primary focus on pediatric patients. This strategy begins with identifying and genetically validating a therapeutic target and using genomics to guide product development. The strategy also involves identifying and acquiring otherwise abandoned or overlooked drug candidates and matching targets and mechanisms of action to novel genetic discoveries. Aevi Genomic has partnered with the Center for Applied Genomics, or CAG, at The Children’s Hospital of Philadelphia, or CHOP, to implement a genomic medicine driven approach to drug developm...

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Aevi Genomic Medicine: Try Subgroups Until It Works?

2018-05-20 seekingalpha
Aevi's current strategy has a reasonable chance of success, but the stock has several red flags and remains highly speculative. (20-0)

Aevi Genomic (GNMX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow

2018-03-29 seekingalpha
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with this event. (16-1)

Aevi Genomic Medicine, Inc. 2017 Q4 - Results - Earnings Call Slides

2018-03-14 seekingalpha
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with their 2017 Q4 earnings call. (16-0)

Aevi Genomic Medicine's (GNMX) CEO Mike Cola on Q4 2017 Results - Earnings Call Transcript

2018-03-13 seekingalpha
Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) Q4 2017 Earnings Conference Call March 13, 2018 8:30 AM ET (16-0)

BRIEF-Aevi Genomic Medicine Reports Q4 Loss Per Share $0.13

2018-03-13 reuters
* AEVI GENOMIC MEDICINE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE (16-0)